These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 21945848)

  • 1. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fosfomycin].
    Gobernado M
    Rev Esp Quimioter; 2003 Mar; 16(1):15-40. PubMed ID: 12750755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.
    Patel SS; Balfour JA; Bryson HM
    Drugs; 1997 Apr; 53(4):637-56. PubMed ID: 9098664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosfomycin: an old--new antibiotic.
    Raz R
    Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.
    Karageorgopoulos DE; Wang R; Yu XH; Falagas ME
    J Antimicrob Chemother; 2012 Feb; 67(2):255-68. PubMed ID: 22096042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
    Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.
    Kunz AN; Brook I
    Chemotherapy; 2010; 56(6):492-500. PubMed ID: 21099222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pattern of antimicrobial susceptibility in uropathogen isolates from children].
    Suárez VM; Suárez RC; Pérez BA; Alvarez FA; Castro SP; Rodríguez FS; Guerrero SM
    Rev Esp Quimioter; 2001 Mar; 14(1):63-8. PubMed ID: 11376352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.